ASX/Media release
2 August 2022

ASX code: PIQ

Clinical Utility Study demonstrates PromarkerD test offers improved treatment options for doctors in the fight against diabetic kidney disease

- **Results published today in the peer-reviewed journal PLOS ONE show the PromarkerD test ranked as more important to physicians than current standard-of-care tests**
- **78% of doctors were very or extremely likely to use PromarkerD in the future for the management of their diabetes patients**
- **The Clinical Utility Study shows the PromarkerD predictive test for diabetic kidney disease could significantly change doctors' treatment decisions and improve outcomes for patients**
- **The published clinical utility study will form a key element of the dossier supporting a United States PLA code reimbursement application for PromarkerD**

Proteomics International Laboratories Ltd (Proteomics International; ASX: PIQ) is pleased to announce that a study demonstrating the clinical utility of the PromarkerD test in predicting diabetic kidney disease was published today in the journal PLOS ONE. PLOS ONE is a peer-reviewed, open access journal published by the Public Library of Science (PLOS), publishing primary research across science and medicine.

PromarkerD is a newly developed blood test that can predict diabetic kidney disease before clinical symptoms appear, and can help doctors make treatment decisions and improve outcomes for patients with type 2 diabetes.

Proteomics International Managing Director Dr Richard Lipscombe said the publication provides important peer-reviewed validation of our initial results that we previously presented at major industry conferences [ASX: 18 October 2021].

"The specialist web-based clinical utility survey shows PromarkerD results ranked as more important to physicians than current standard-of-care tests eGFR (estimated glomerular filtration rate) and ACR (urinary albumin - creatinine ratio)."

Senior author of the study Dr Alexander Turchin, an endocrinologist at Boston's Brigham and Women's Hospital, said PromarkerD allows earlier targeted treatment for patients at high risk of diabetic kidney disease, while avoiding unnecessary interventions for people at low risk.

"*When presented with moderate or high-risk PromarkerD results, physicians were more likely to implement renoprotective changes—such as increasing monitoring frequency, prescribing SGLT2 inhibitors or replacing ibuprofen—than if they did not have the PromarkerD test results,"* he said.

"*These changes can help avoid end-stage interventions such as dialysis and kidney transplant. In contrast, when presented with low-risk PromarkerD results, the likelihood of aggressive treatment and health care resource utilisation reduced*."

The clinical utility study, performed in collaboration with Veranex Solutions (formerly Boston Healthcare Associates), surveyed 400 primary care physicians and endocrinologists in the United States. The physicians

were asked to assess 42 real-life scenarios for patients with type 2 diabetes.

The study found PromarkerD risk scores would significantly impact physician decision-making - 78% of physicians in the study said they were very or extremely likely to order the PromarkerD test for their type 2 diabetes patients, with only 2% indicating they would not order the test. The PromarkerD results consistently ranked as the first- or second-most important attribute driving physician decision-making across the specified outcomes of disease monitoring frequency, prescription of renal protective drugs (SGLT2 inhibitors) and ongoing use of other drugs for diabetes management, such as ACE-inhibitors and ibuprofen.

The clinical utility study forms an important part of the Proteomics International's ongoing strategy for the roll-out of PromarkerD in the United States. The publication will support the Company's application for a Proprietary Laboratory Analyses (PLA) reimbursement code, which is necessary for the broad reimbursement of the PromarkerD test by insurance companies and other payors in the US.

The full paper titled '*Evaluation of the clinical utility of the PromarkerD in-vitro test in predicting diabetic kidney disease and rapid renal decline through a conjoint analysis*' is available online[1] from PLOS ONE.

Authorised by the Board of Proteomics International Laboratories Ltd (ASX.PIQ).

ENDS

About PromarkerD (www.PromarkerD.com)
Diabetic kidney disease (DKD) is a serious complication arising from diabetes which if unchecked can lead to dialysis or kidney transplant. PromarkerD is a prognostic test that can predict future kidney function decline in patients with type 2 diabetes and no existing DKD. The patented PromarkerD test system uses a simple blood test to detect a unique 'fingerprint' of the early onset of the disease by measuring three serum protein biomarkers, combined with three routinely available conventional clinical variables (age, HDL-cholesterol and estimated glomerular filtration rate (eGFR)). A cloud based algorithm integrates the results into a patient risk report. In clinical studies published in leading journals PromarkerD correctly predicted up to 86% of otherwise healthy diabetics who went on to develop diabetic kidney disease within four years. The PromarkerD test is CE Mark registered in the European Union.

Further information is available through the PromarkerD web portal.

To visit the PromarkerD virtual booth please see: www.PromarkerD.com/product

About Proteomics International Laboratories (PILL) (www.proteomicsinternational.com)
Proteomics International (Perth, Western Australia) is a wholly owned subsidiary and trading name of PILL (ASX: PIQ), a medical technology company at the forefront of predictive diagnostics and bio-analytical services. The Company specialises in the area of proteomics – the industrial scale study of the structure and function of proteins. Proteomics International's mission is to improve the quality of lives by the creation and application of innovative tools that enable the improved treatment of disease.

For further information please contact:
Dr Richard Lipscombe
Managing Director
Proteomics International Laboratories Ltd
T: +61 8 9389 1992
E: enquiries@proteomicsinternational.com

Dirk van Dissel
Investor Relations & Corporate Advisor
Candour Advisory
T: +61 408 326 367
E: dirk@candouradvisory.com.au

Kyle Moss
Corporate Advisor
Euroz Hartleys
T: +61 8 9488 1400
E: kmoss@eurozhartleys.com

[1] doi.org/10.1371/journal.pone.0271740